TrialThe Lancet. Oncology2017
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Julie R Brahmer et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
198 papers cite itlatest 60 shown
this paperpooled ittrialcites it